Yom Chai’s objective is to conduct pre-clinical research and clinical trials in Israel utilizing extracted components from diverse cannabis cultivars with specific cannabinoid and terpene profiles to treat patients with various diseases. The company has world leading cannabis scientific team, with expertise in pre-clinical research and clinical trial design.
We will be focused on three main categories: (1) Gastrointestinal, (2) Neurodevelopmental and (3) Neurodegenerative. Yom Chai will have significant advantages and greater possibilities of having one or multiple successful outcomes with the professional team they have put in place. Yom Chai’s partners span every aspect of the industry from concept to market. Cumulatively the team possess more than 20-years’ experience in the cannabis industry. The company is led by the Executive Management team with the support of cultivators, scientists, laboratories,formulation team, hospitals and universities in Israel. The Executive Management team consists of founders Scot Albert (Managing Partner), Lori Albert (Managing Partner), and Garrett Seale (Chief Science Officer).
Followed by the scientific and formulating team which will consist of iCANN, CannaTech, EndoCRO, CANNRX, Steep Hill, and Kaneh-B. The time frame for each trial will be up to two years for completion. The data obtained while the clinical trials are being conducted will be utilized for direct formulation to create full-spectrum medical cannabis products.
Yom Chai will be targeting people suffering from Crohn’s Disease and will develop various targeted cannabis formulations including treatment for children and adults with Autism Spectrum Disorders (ASD), Attention Deficit Hyperactivity Disorder (ADHD), Psoriasis and Sleep.